Migdal Insurance & Financial Holdings Ltd. Intellia Therapeutics, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$7.12 Billion
Q1 2025

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$60.88 - $161.91 $961,904 - $2.56 Million	-15,800 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$46.59 - $83.68 $456,814 - $820,482	9,805 Added 163.55%	15,800 $1.27 Million
Q4 2020 Feb 08, 2021	BUY	$18.83 - $63.53 $112,885 - $380,862	5,995 New	5,995 $326,000

Others Institutions Holding NTLA

# of Institutions

344

Shares Held

98.4M

Call Options Held

784K

Put Options Held

713K

Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

13M
Shares

$126 Million
1.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.8M
Shares

$104 Million
0.0% of portfolio
Black Rock Inc. New York, NY

9.6M
Shares

$92.8 Million
0.0% of portfolio
State Street Corp Boston, MA

4.51M
Shares

$43.6 Million
0.0% of portfolio
Morgan Stanley New York, NY

3.8M
Shares

$36.8 Million
0.0% of portfolio

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $735M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account